


**Product Name** : E7449  
**Cat. No.** : PC-43025  
**CAS No.** : 1140964-99-3  
**Molecular Formula** : C<sub>18</sub>H<sub>15</sub>N<sub>5</sub>O  
**Molecular Weight** : 317.3446  
**Target** : PARP  
**Solubility** : DMSO: < 6.96 mg/mL



## Biological Activity

E7449 (Stenoparib, 2X-121) is a potent, orally bioavailable, brain penetrable dual inhibitor of **PARP1/2** and **TNKS1/2** with IC<sub>50</sub> of 2.0/1.0 nM (PARP1/2), 50-100 nM (TNKS1/2).

E7449 (Stenoparib, 2X-121) displays no significant inhibitory activity for PARP3 or PARPs6-16.

E7449 (Stenoparib, 2X-121) shows sensitivity to cells deficient in DNA repair pathways beyond homologous recombination, inhibits Wnt/ $\beta$ -catenin signaling in colon cancer cell lines, stabilizes axin and TNKS proteins resulting in  $\beta$ -catenin destabilization and significantly alters expression of Wnt target genes.

E7449 (Stenoparib, 2X-121) potentiates antitumor activity of chemotherapies temozolomide and carboplatin both in vitro and in vivo.

## References

McGonigle S, et al. *Oncotarget*. 2015 Dec 1;6(38):41307-23.

2. Sharon McGonigle, et al. Abstract 4688: E7449: A novel PARP inhibitor enhances the efficacy of radiotherapy and chemotherapy and has potent single agent anticancer activity in BRCA-deficient tumors . *Cancer Research*: April 15, 2012; Volume 72, Issue 8, Su

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com